NCT06135194View on ClinicalTrials.gov

Efficacy of T-Dxd in the Treatment of HER2-positive BCBM After Prior Pyrotinib

RecruitingOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

December 30, 2023

Study Completion Date

June 30, 2024

Conditions
Breast Cancer
Interventions
DRUG

T-DXd

Efficacy and safety of T-DXd in the treatment of HER2-positive breast cancer with brain metastases after treatment with pyrotinib

Trial Locations (2)

100071

RECRUITING

The Fifth Medical Center of PLA General Hospital, Beijing

RECRUITING

The Fifth Medical Center of PLA General Hospital, Beijing

All Listed Sponsors
lead

Beijing 302 Hospital

OTHER